Harvard Bioscience
HBIO
60 hedge funds and large institutions have $54.2M invested in Harvard Bioscience in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 6.2% → 6.14% (-0.06%)
3% less capital invested
Capital invested by funds: $55.8M → $54.2M (-$1.55M)
3% less funds holding
Funds holding: 62 → 60 (-2)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$1.08M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$910K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$729K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$474K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.78M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.28M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$1.1M |
| 4 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$171K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$160K |
HBIO Hedge Fund Activity: Q2 2017 in Review
60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2017, worth a combined $54.2M — down 2.8% from $55.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HBIO and 4 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was Segall Bryant & Hamill, adding an estimated $1.08M. The largest seller was Granahan Investment Management, cutting an estimated $1.78M.
- 60 institutional investors held Harvard Bioscience (HBIO) as of Q2 2017, down from 62 in Q1 2017.
- Funds reported $54.2M of Harvard Bioscience stock for Q2 2017, down 2.8% quarter-over-quarter.
- 4 funds opened new Harvard Bioscience positions in Q2 2017 and 6 closed out, a net change of -2 holders.
- The largest Harvard Bioscience buyer in Q2 2017 was Segall Bryant & Hamill, an estimated $1.08M added.
- The largest Harvard Bioscience seller in Q2 2017 was Granahan Investment Management, an estimated $1.78M sold.
Based on aggregated 13F filings for Q2 2017.